Use of a new rifamycin SV derivative in chronic urinary infections.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001437:Bacteriuria / Q000188:drug therapy*; D002512:Cephalothin / Q000627:therapeutic use; D002701:Chloramphenicol / Q000627:therapeutic use; D002908:Chronic Disease; D003091:Colistin / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004927:Escherichia coli Infections / Q000188:drug therapy*; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007612:Kanamycin / Q000627:therapeutic use; D008297:Male; D008690:Methacycline / Q000627:therapeutic use; D008875:Middle Aged; D010118:Oxytetracycline / Q000627:therapeutic use; D011512:Proteus Infections / Q000188:drug therapy*; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D013421:Sulfamethoxypyridazine / Q000627:therapeutic use; D014552:Urinary Tract Infections / Q000188:drug therapy*
D005839:Gentamicins; D007612:Kanamycin; D002701:Chloramphenicol; D008690:Methacycline; D002512:Cephalothin; D013421:Sulfamethoxypyridazine; D012293:Rifampin; D010118:Oxytetracycline; D003091:Colistin